| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCDC80 |
| Uniprot No | Q76M96 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-950aa |
| 氨基酸序列 | MTWRMGPRFTMLLAMWLVCGSEPHPHATIRGSHGGRKVPLVSPDSSRPARFLRHTGRSRGIERSTLEEPNLQPLQRRRSVPVLRLARPTEPPARSDINGAAVRPEQRPAARGSPREMIRDEGSSARSRMLRFPSGSSSPNILASFAGKNRVWVISAPHASEGYYRLMMSLLKDDVYCELAERHIQQIVLFHQAGEEGGKVRRITSEGQILEQPLDPSLIPKLMSFLKLEKGKFGMVLLKKTLQVEERYPYPVRLEAMYEVIDQGPIRRIEKIRQKGFVQKCKASGVEGQVVAEGNDGGGGAGRPSLGSEKKKEDPRRAQVPPTRESRVKVLRKLAATAPALPQPPSTPRATTLPPAPATTVTRSTSRAVTVAARPMTTTAFPTTQRPWTPSPSHRPPTTTEVITARRPSVSENLYPPSRKDQHRERPQTTRRPSKATSLESFTNAPPTTISEPSTRAAGPGRFRDNRMDRREHGHRDPNVVPGPPKPAKEKPPKKKAQDKILSNEYEEKYDLSRPTASQLEDELQVGNVPLKKAKESKKHEKLEKPEKEKKKKMKNENADKLLKSEKQMKKSEKKSKQEKEKSKKKKGGKTEQDGYQKPTNKHFTQSPKKSVADLLGSFEGKRRLLLITAPKAENNMYVQQRDEYLESFCKMATRKISVITIFGPVNNSTMKIDHFQLDNEKPMRVVDDEDLVDQRLISELRKEYGMTYNDFFMVLTDVDLRVKQYYEVPITMKSVFDLIDTFQSRIKDMEKQKKEGIVCKEDKKQSLENFLSRFRWRRRLLVISAPNDEDWAYSQQLSALSGQACNFGLRHITILKLLGVGEEVGGVLELFPINGSSVVEREDVPAHLVKDIRNYFQVSPEYFSMLLVGKDGNVKSWYPSPMWSMVIVYDLIDSMQLRRQEMAIQQSLGMRCPEDEYAGYGYHSYHQGYQDGYQDDYRHHESYHHGYPY |
| 预测分子量 | 108 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCDC80重组蛋白的3篇参考文献(信息基于公开发表的文献整理，非真实文献引用，仅作示例参考)：
1. **文献名称**: *CCDC80重组蛋白在血管生成中的作用机制研究*
**作者**: Zhang L, et al.
**摘要**: 研究通过体外重组表达CCDC80蛋白，发现其通过调节VEGF信号通路抑制内皮细胞迁移和血管形成，提示其在抗肿瘤血管治疗中的潜在应用。
2. **文献名称**: *重组CCDC80蛋白对脂肪细胞分化的调控功能*
**作者**: Wang Y, et al.
**摘要**: 实验表明重组CCDC80蛋白可通过激活Wnt/β-catenin通路抑制前脂肪细胞分化，为肥胖及相关代谢疾病的治疗提供新靶点。
3. **文献名称**: *CCDC80重组蛋白在心肌纤维化中的保护作用*
**作者**: Chen H, et al.
**摘要**: 在小鼠模型中，外源性重组CCDC80蛋白通过抑制TGF-β/Smad3通路减轻心肌纤维化，提示其作为心脏疾病治疗分子的潜力。
(注：以上为模拟示例，实际文献需通过PubMed、Web of Science等平台检索确认。)
**Background of CCDC80 Recombinant Protein**
CCDC80 (Coiled-Coil Domain-Containing 80), also known as CL2. LCCL, or URIP, is a secreted extracellular matrix protein encoded by the *CCDC80* gene. It is characterized by multiple functional domains, including a signal peptide, SR (serine-rich) domains, and coiled-coil motifs, which facilitate its interaction with other extracellular components like collagens, proteoglycans, and integrins. CCDC80 plays a critical role in modulating cell adhesion, migration, and tissue remodeling, linking the extracellular matrix to intracellular signaling pathways.
Recombinant CCDC80 protein is engineered using expression systems (e.g., bacterial, mammalian, or insect cells) to produce purified, bioactive forms of the protein for research and therapeutic applications. Its recombinant production allows precise study of its structure-function relationships, particularly its roles in tissue homeostasis, inflammation, and cancer. Studies suggest CCDC80 acts as a tumor suppressor in certain cancers by inhibiting Wnt/β-catenin signaling, while also promoting endothelial cell function and angiogenesis in cardiovascular contexts.
Aberrant CCDC80 expression has been linked to metabolic disorders, fibrosis, and autoimmune diseases, highlighting its regulatory importance. Recombinant CCDC80 is utilized in vitro and in vivo to explore its therapeutic potential in tissue repair, anti-inflammatory therapies, or as a biomarker for disease progression. Current research focuses on optimizing its stability, delivery mechanisms, and clarifying its dual roles in different pathological contexts. Ongoing preclinical studies aim to harness recombinant CCDC80 for regenerative medicine or targeted cancer therapies, underscoring its versatility as a multifunctional signaling modulator.
×
